Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA; School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Adv Drug Deliv Rev. 2020;156:23-39. doi: 10.1016/j.addr.2020.05.005. Epub 2020 May 22.
Cancer is one of the most severe disease burdens in modern times, with an estimated increase in the number of patients diagnosed globally from 18.1 million in 2018 to 23.6 million in 2030. Despite a significant progress achieved by conventional therapies, they have limitations and are still far from ideal. Therefore, safe, effective and widely-applicable treatments are urgently needed. Over the past decades, the development of novel delivery approaches based on membrane-core (MC) nanostructures for transporting chemotherapeutics, nucleic acids and immunomodulators has significantly improved anticancer efficacy and reduced side effects. In this review, the formulation strategies based on MC nanostructures for delivery of anticancer drug are described, and recent advances in the application of MC nanoformulations to overcome the delivery hurdles for clinical translation are discussed.
癌症是现代最严重的疾病负担之一，据估计，全球 2018 年被诊断出的癌症患者人数为 1810 万，到 2030 年将增至 2360 万。尽管传统疗法取得了显著进展，但它们仍存在局限性，远非理想。因此，急需安全、有效且适用范围广泛的治疗方法。在过去几十年中，基于膜核（MC）纳米结构的新型递药方法的发展，显著提高了癌症治疗的疗效，降低了副作用。本综述描述了基于 MC 纳米结构的抗癌药物递药的制剂策略，并讨论了 MC 纳米制剂在克服临床转化递药障碍方面的最新进展。
